NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.